SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artŪculo

MANGERA, Altaf  y  CHAPPLE, Christopher R.. Uso de la toxina botulínica en el tratamiento de los trastornos del tracto urinario inferior: Situación actual. Arch. Esp. Urol. [online]. 2010, vol.63, n.10, pp.829-841. ISSN 0004-0614.

    *1. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB: Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996;155:1023-1029. [ Links ]

    *2. Schurch B, Schmid DM, Stohrer M: Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000;342:665. [ Links ]

    3. Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 2005;5:274-279. [ Links ]

    4. Harper M, Fowler CJ, Dasgupta P: Botulinum toxin and its applications in the lower urinary tract. BJU Int 2004;93:702-706. [ Links ]

    5. Kumar V, Chapple CC, Chess-Williams R: Characteristics of adenosine triphosphate [corrected] release from porcine and human normal bladder. J Urol 2004;172:744-747. [ Links ]

    *6. Kumar V, Cross RL, Chess-Williams R, Chapple CR: Recent advances in basic science for overactive bladder. Curr Opin Urol 2005;15:222-226. [ Links ]

    7. Kumar V, Chapple C C-WR: Distribution of purinergic receptors in urinary bladder of porcine and normal human urinary bladder. Europaen urology supplements 2004;3:76. [ Links ]

    8. Fowler CJ: Bladder afferents and their role in the overactive bladder. Urology 2002;59:37-42. [ Links ]

    9. Kumar V, Chapple C C-WR: Distribution of purinergic receptors in urinary bladder of porcine and normal human urinary bladder. Europaen urology supplements 2004;3:76. [ Links ]

    10. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP: Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004;45:987-993. [ Links ]

    11. Atiemo H, Wynes J, Chuo J, Nipkow L, Sklar GN, Chai TC: Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology 2005;65:622-626. [ Links ]

    12. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P: Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977-982. [ Links ]

    13. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB: Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004;64:871-875. [ Links ]

    14. Vemulakonda VM, Somogyi GT, Kiss S, Salas NA, Boone TB, Smith CP: Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 2005;173:621-624. [ Links ]

    15. Smith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB, Somogyi GT: Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003;169:1896-1900. [ Links ]

    16. Sahai A, Khan M, Fowler CJ, Dasgupta P: Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn 2005;24:2-12. [ Links ]

    17. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P: Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977-982. [ Links ]

    18. Giannantoni A, Nardicchi v, Di Stasi S, Macchioni L MEGF: Botulinum toxin A intravesical injections reduce nerve growth factor bladder tissue content in patietnts affected by neurogenic detrusor overactivity; 2005, p 221. [ Links ]

    *19. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139:919-922. [ Links ]

    *20. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB: Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996;155:1023-1029. [ Links ]

    21. Petit H, Wiart L, Gaujard E, Le BF, Ferriere JM, Lagueny A, Joseph PA, Barat M: Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 1998;36:91-94. [ Links ]

    22. Kuo HC: Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 2003;170:1908-1912. [ Links ]

    23. de SM, Petit H, Gallien P, de Seze MP, Joseph PA, Mazaux JM, Barat M: Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 2002;42:56-62. [ Links ]

    *24. Kuo HC: Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn 2008;27:793-796. [ Links ]

    *25. Fowler CJ, Betts CD, Christmas TJ, Swash M, Fowler CG: Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 1992;70:387-389. [ Links ]

    26. Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N, Chancellor MB: Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001;165:1107-1110. [ Links ]

    27. Kuo HC: Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 2003;61:550-554. [ Links ]

    28. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-697. [ Links ]

    **29. Schurch B, de SM, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF: Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196-200. [ Links ]

    **30. Reitz A, Stohrer M, Kramer G, Del PG, Chartier-Kastler E, Pannek J, Burgdorfer H, Gocking K, Madersbacher H, Schumacher S, Richter R, von TJ, Schurch B: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510-515. [ Links ]

    31. Giannantoni A, Mearini E, Del ZM, Porena M: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009;55:705-711. [ Links ]

    32. Game X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudie I, De B, X, Malavaud B, Marque P, Rischmann P: Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008;53:613-618. [ Links ]

    *33. Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, Warner J, Elneil S, Fowler CJ, Dasgupta P: Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49:519-527. [ Links ]

    34. Boy S, Seif P, Braun: Retrospective Analysis of treatment outcomes and medical care of patients with neurogenic detrusor overactivity (NDO) receiving BOTOX therapy; 2008. [ Links ]

    35. Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L, Bauer SB: Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004;171:845-848. [ Links ]

    36. Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH: Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002;59:325-327. [ Links ]

    37. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH: Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003;44:139-143. [ Links ]

    *38. Radziszewski P, Borowski A: Botulinum toxin type A intravesical injections for intractable bladder overactivity.; 2002, p 134. [ Links ]

    39. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984-989. [ Links ]

    40. Chancellor MB, O' Leary M, Erickson J, Cannon TW CC, Leng WW: Successful Use of Bladder Botulinum Toxin Injection To Treat Refractory Overactive Bladder; 2003. [ Links ]

    **41. Sahai A, Dowson C, Khan MS, Dasgupta P: Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009;103:1509-1515. [ Links ]

    42. Werner M, Schmid DM, Schussler B: Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005;192:1735-1740. [ Links ]

    **43. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J: Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-222. [ Links ]

    *44. Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006;176:177-185. [ Links ]

    45. Cohen BL, Barboglio P, Rodriguez D, Gousse AE: Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009;28:205-208. [ Links ]

    *46. Kuo HC: Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005;66:94-98. [ Links ]

    47. Schulte-Baukloh H, Weiss C, Stolze T, Sturzebecher B, Knispel HH: Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005;66:82-87. [ Links ]

    *48. Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT: Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004;63:1071-1075. [ Links ]

    49. Hoebke P, Decaestecker K, Verleyen P: Extended experience with the use of botulinum toxin A in children with non neurogenic voiding dysfunction; 2005. [ Links ]

    50. Peeren F, Everaert K, Hoebke P: Successive Injections of Botulinum A Toxine (Botox) in Paediatric Population.; 2005. [ Links ]

    51. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M: Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 2006;49:704-709. [ Links ]

    52. Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E: Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 2008;179:1031-1034. [ Links ]

    53. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB: Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004;64:871-875. [ Links ]

    54. Kuo HC, Chancellor MB: Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 2009;104:657-661. [ Links ]

    55. Maria G, Destito A, Lacquaniti S, Bentivoglio AR, Brisinda G, Albanese A: Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 1998;352:625. [ Links ]

    56. Smith CP, Chancellor MB: Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004;171:2128-2137. [ Links ]

    57. Aoki KR, Guyer B: Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8 Suppl 5:21-29. [ Links ]

    58. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA: Botox-induced prostatic involution. Prostate 1998;37:44-50. [ Links ]

    *59. Maria G, Cadeddu F, Brisinda D, Brandara F, Brisinda G: Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin. Curr Med Chem 2005;12:247-265. [ Links ]

    **60. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259-264. [ Links ]

    61. Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB: Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005;66:775-779. [ Links ]

    62. Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, Cruz F: Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 2008;53:153-159. [ Links ]

    63. Kuo HC: Prostate botulinum A toxin injection-an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005;65:670-674. [ Links ]

    64. Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R, Silva C, Cruz F, Dinis P: Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol 2009;9:9. [ Links ]

    65. Leippold T, Reitz A, Schurch B: Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003;44:165-174. [ Links ]

    66. Silberstein SD, Aoki KR: Botulinum toxin type A: myths, facts, and current research. Headache 2003;43 Suppl 1:S1. [ Links ]

    67. Reitz A, Schurch B: Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 2004;171:804-805. [ Links ]

    68. Grosse J, Kramer G, Stohrer M: Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47:653-659. [ Links ]

    69. Del PG, Filocamo MT, Li M, V, Macchiarella A, Cecconi F, Lombardi G, Nicita G: Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol 2008;53:1013-1019. [ Links ]

    70. Truzzi JC, Bruschini H, Siminetti R, Miguel S: What is the best dose for intravesical botulinum-A toxin injection in overactive bladder treatment? A prospective randomised preliminary study.; 2004. [ Links ]

    71. Gousse A, Tunuguntla HSGR, Rodriguez D, Valzquez D: Detrusor injection of botulinum A toxin for idiopathic overactive bladder syndrome: Clinical and urodynamic evaluation.; 2005. [ Links ]

    72. Pistolesi D, Selli C, Rossi B, Stampacchia G: Botulinum toxin type B for type A resistant bladder spasticity. J Urol 2004;171:802-803. [ Links ]

    73. Hirst G, Wareham K, Emery S, Lucas M: Failure of Botulinum Toxin Type B in the Treatment of the Refractory Overactive Bladder; 2005. [ Links ]

    74. Dykstra D, Enriquez A, Valley M: Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:424-426. [ Links ]

    **75. Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, Shah PJ, Malone-Lee J: Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005;174:1873-1877. [ Links ]

    76. Kuo HC: Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004;63:868-872. [ Links ]

    77. Karsenty G, Boy S, Reitz A, Knapp P, Bardot P, Tournebise H: Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-A prospective randomized study to compare 30 vs. 10 injection sites; 2005. [ Links ]

    78. Reitz A, Stohrer M, Kramer G, Del PG, Chartier-Kastler E, Pannek J, Burgdorfer H, Gocking K, Madersbacher H, Schumacher S, Richter R, von TJ, Schurch B: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510-515. [ Links ]

    79. Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P: A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003;92:325-326. [ Links ]

    *80. Zermann DH, Ishigooka M, Schmidt RA: Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency ; 2001, pp 412-413. [ Links ]

    *81. Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J: Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007;177:1011-1014. [ Links ]

    82. Kennelly MJ, Kang J: Botulinum-A toxin injections as a treatment for refractory detrusor hyperreflexia. Top Spinal Cond Inj Rehabil 2003;4:46-53. [ Links ]

    83. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC: Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005;24:231-236. [ Links ]

    84. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984-989. [ Links ]

    85. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M: Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004;172:240-243. [ Links ]

    86. Wyndaele JJ, Van Dromme SA: Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40:599-600. [ Links ]

    87. Rackley R, Abdelmalak J: Urologic applications of botulinum toxin therapy for voiding dysfunction. Curr Urol Rep 2004;5:381-388. [ Links ]

    88. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B: Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006;68:1193-1197. [ Links ]

    89. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E: Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007;52:1729-1735. [ Links ]

    90. Haferkamp A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G, Schumacher S, Bastian PJ, Buttner R, Muller SC, Stohrer M: Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004;46:784-791. [ Links ]

    91. Comperat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E: Histologic features in the urinary bladder wall affected from neurogenic overactivity-a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006;50:1058-64. [ Links ]

    92. Apostolidis A, Jacques TS, Freeman A, Kalsi V, Popat R, Gonzales G, Datta SN, Ghazi-Noori S, Elneil S, Dasgupta P, Fowler CJ: Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008;53:1245-1253. [ Links ]